Neothetics (NASDAQ:NEOT) last announced its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.20) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.20).
Neothetics, Inc. (NASDAQ NEOT) opened at $1.27 on Monday. Neothetics, Inc. has a 12 month low of $0.30 and a 12 month high of $2.63.
WARNING: “Neothetics, Inc. (NEOT) Scheduled to Post Earnings on Wednesday” was published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/11/06/neothetics-inc-neot-scheduled-to-post-earnings-on-wednesday.html.
Separately, ValuEngine raised Neothetics from a “strong sell” rating to a “sell” rating in a research note on Tuesday, October 17th.
Neothetics Company Profile
Neothetics, Inc is a clinical-stage specialty pharmaceutical company, which develops therapeutics. The Company focuses on localized fat reduction and body contouring. It focuses on the development of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese patients.
What are top analysts saying about Neothetics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Neothetics Inc. and related companies.